Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits

Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA’s full and partial clinical holds on a Phase I/II trial for the treatment.The FDA last month imposed a full clinical hold on the IGNITE DMD trial after the first patient dosed with SGT-001 was hospitalized “due to laboratory findings that included a decrease in platelet count followed by a reduction in red blood cell count and ev